slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 45,391-45,420
Pages 2,019
Rows per page 30
Component
45,391-45,420 of 60,568
17
Honest | Investor Presentation Deck | 31 slidesHonest | Investor Presentation Deck | 31 slides · Honest
Pitch deck Investor relations Beat · The Breakthrough1 hit
18
Honest | Investor Presentation Deck | 31 slidesHonest | Investor Presentation Deck | 31 slides · Honest
Pitch deck Investor relations Beat · The Breakthrough1 hit
31
The table shows adjustments for non-cash and non-recurring items like stock-based compensation, litigation, and restructuring.Honest | Investor Presentation Deck | 31 slides · Honest
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
06
The table shows a deteriorating cash position over 12 weeks, ending in a negative balance of ($8.5M) after accounting for a $4M contingency.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Situation & Context1 hit
07
Includes a disclaimer about potential investors and a footnote regarding Customer A.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Situation & Context1 hit
10
Houlihan Lokey | Investment Banking Pitch Book | 25 slidesHoulihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Pattern Hunter1 hit
11
The table highlights a deteriorating cash position over the 12-week period, ending in a significant deficit.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem & Complication1 hit
13
The slide presents a range of recovery outcomes (Low vs High) based on book values as of 12/31/23.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Evidence & ProofLoop · Mece Breakdown1 hit
14
Includes footnotes detailing the basis of the analysis and specific debt terms.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Evidence & ProofLoop · Mece Breakdown1 hit
18
The slide uses a dual-axis chart (price and volume) combined with a detailed event log table.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
19
The slide includes a line chart showing performance over time and a summary table with specific return metrics for three different time periods.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
20
The table compares revenue, cost of revenue, gross profit, operating expenses, and adjusted EBITDA across two time periods.Houlihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
21
Houlihan Lokey | Investment Banking Pitch Book | 25 slidesHoulihan Lokey | Investment Banking Pitch Book | 25 slides · Houlihan Lokey
Consulting deck Investment bank 1 hit
12
The slide highlights an upward revision in financial targets for Group Sales, Sales Growth, EBIT, and EBIT Margin.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Problem1 hit
72
Hugo Boss | Investor Presentation Deck | 99 slidesHugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
90
The slide uses a 3x3 grid layout to categorize distribution methods.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
91
Hugo Boss | Investor Presentation Deck | 99 slidesHugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
92
The slide highlights the total number of retail points of sale (1,418) for 2023.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
95
The slide uses a comparison table structure to contrast STI and LTI components.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
97
The table highlights 2023 data in a distinct brown column.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
98
Data table extracted from Hugo Boss Annual Report 2023.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
29
The slide uses a clean table layout to compare FY 2023 absolute values and year-over-year changes.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style chart to represent clinical trial stages.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
08
The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
Includes a footnote citing FDA approval precedents for single-arm studies.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
29
The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Includes a comparative table of clinical outcomes (ORR, CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The table highlights low incidence of severe adverse events and management protocols for NXC-201.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit